TXMD
TherapeuticsMD, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$2.20
−1.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.3M | 3.0M | 1.8M | 1.3M | 70.0M |
| Cost of Revenue | 329.0K | — | — | — | 1.4M |
| Gross Profit | 2.9M | 3.0M | 1.8M | 1.3M | 68.6M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 6.7M | 6.9M | 6.1M | 8.9M | 56.7M |
| General & Admin Expense | 6.7M | 6.9M | 6.1M | — | 57.9M |
| Selling & Marketing Expense | — | — | — | — | (1.2M) |
| Other Expenses | 53.0K | 384.0K | 509.0K | 922.0K | 1.2M |
| Total Operating Expenses | 6.8M | 7.2M | 6.6M | 9.8M | 57.9M |
| Cost and Expenses | 7.1M | 7.2M | 6.6M | 9.8M | 59.3M |
| Operating Income (EBIT) | (3.9M) | (4.2M) | (4.8M) | (8.5M) | 10.7M |
| Non-Operating | |||||
| Interest Income | 110.0K | 150.0K | — | 300.0K | — |
| Interest Expense | 4.0K | 8.0K | — | 200.0K | — |
| Net Interest Income | 106.0K | 142.0K | — | 100.0K | — |
| Other Non-Op Income/Expense | 3.6M | 3.6M | 2.5M | 781.0K | (9.6M) |
| Non-Operating Income (excl Interest) | 1.8M | — | — | — | — |
| EBT (Pre-Tax Income) | (263.0K) | (653.0K) | (2.3M) | (7.7M) | 1.1M |
| Income Tax Expense | 32.0K | — | (31.0K) | (43.0K) | — |
| Bottom Line | |||||
| Net Income | (217.0K) | (569.0K) | (2.2M) | (10.3M) | 112.0M |
| Earnings from Cont. Ops | (295.0K) | (653.0K) | (2.3M) | (7.7M) | 1.1M |
| Earnings from Discont. Ops | 78.0K | 84.0K | 131.0K | (2.6M) | 110.9M |
| Bottom Line Net Income | (217.0K) | (569.0K) | (2.2M) | (10.3M) | 112.0M |
| Per Share | |||||
| Basic EPS | ($0.02) | ($0.05) | ($0.19) | ($0.55) | $12.41 |
| Diluted EPS | ($0.02) | ($0.05) | ($0.19) | ($0.74) | $12.41 |
| Revenue Per Share | $0.28 | $0.26 | $0.15 | $0.12 | $7.75 |
| Shares | |||||
| Basic Shares Outstanding | 11.6M | 11.6M | 11.5M | 10.4M | 9.0M |
| Diluted Shares Outstanding | 11.6M | 11.6M | 11.5M | 10.4M | 9.0M |
| Profitability Metrics | |||||
| EBITDA | (4.2M) | (3.0M) | (3.6M) | (7.6M) | 11.9M |
| D&A | 1.4M | 1.2M | 1.3M | 922.0K | 1.2M |
| EBIT | (5.6M) | (4.2M) | (4.8M) | (8.5M) | 10.7M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026